Share this story:

Global Cannabis Applications to be showcased on 'Advancements with Ted Danson' on Saturday, September 25, 2021, at 2:30 PM ET



Global Cannabis Applications Corp.

Efixii technology highlighted on CNBC broadcast to reach 85 million homes

 

Vancouver, British Columbia, Canada - TheNewswire - September 21, 2021 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CNSX:APP.CN) (FSE:2FA) (OTC:FUAPF), a leading cannabis chain-of-custody compliance and data platform, announced that the ‘Advancements’ TV Series [1], hosted by Golden Globe-winning actor Ted Danson [2], will explore how GCAC developed its patent-pending Efixii smartphone app and the benefits it brings to the cannabis sector. Up to 85 million viewers will learn how Efixii reduces cannabis cultivator’s compliance costs, and how improved product consistency leads to higher profitability. They also learn how cannabis consumers reliably feedback their consumption experience to cultivators using the Efixii app, and how GCAC technology actually leads to better consumer and patient outcomes.

GCAC’s CEO Brad Moore says, “We’re excited to be able to speak directly to millions of CNBC viewers that currently use cannabis and to address millions of other potential cannabis consumers who may be reluctant to try cannabis. We’re aiming to give everyone some peace of mind about medical and recreational cannabis, and its benefits when cultivated and consumed in conjunction with Efixii. And, if cannabis is offered as a medical treatment, both patient and clinician should know precisely what’s in the medication, and this is what Efixii can bring. Consumers everywhere should ensure their cannabis has an Efixii QR code on the package, so they know exactly how it was grown, what it contains, and where they can read independent efficacy feedback from others.”  

Shining a light on several important issues and topics currently impacting society, ‘Advancements’ covers a vast number of industries and economies, featuring state-of-the-art technologies and solutions dedicated to shaping, molding, and transforming the world. Aiming to create a new level of social awareness, ‘Advancements’ brings this vital information to the public in an effort to educate on the effects of such significant contributions.

GCAC’s full-length feature segment will air Nationwide in the U.S. during a half-hour episode of ‘Advancements’ to millions of television households, reaching approximately 200-million subscribers or more via DISH Network, DIRECTV, Verizon FiOS TV, and more than 600 independent rural cable systems. Additionally, the episode is distributed internationally through Voice of America, the official external broadcast institution of the U.S. federal government.

Efixii is licensed to cultivators in a SaaS model and is a free-to-use app for cannabis consumers. Efixii’s cannabis efficacy data is the intellectual property (“IP”) of GCAC. This IP creates an inherent difficulty in replicating or competing with GCAC’s cannabis datasets. GCAC defined their protocols in a provisional U.S. patent application, ‘System of Process and Tracking Cannabis Products and Associated Method Using Blockchain’ filed with the USPTO on Dec. 17, 2020.

[1] http://advancementstv.com/

[2] https://twitter.com/TedDanson

About Advancements and DMG Productions:
The Advancements television series is an information-based educational program, targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world. Backed by experts in various fields, and a team dedicated to education and advancement, DMG Productions consistently produces commercial-free, educational programming on which both viewers and networks depend.

About Global Cannabis Applications Corp. “GCAC”

GCAC is a global leader in designing, developing, SaaS licensing, and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain, and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology, and acquiring high-quality cannabis datasets that improve patient outcomes and become the world’s largest cannabis efficacy data provider.

For more Company information, please visit www.cannappscorp.com, or review its profiles on www.sedar.com and on the Canadian Securities Exchange's website www.thecse.com.

 

Press Contact

 Phone: +1 (800) 409-5679

 Email: info@cannappscorp.com

Forward-Looking Information 

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.